Rhythm Pharmaceuticals (RYTM) Cash from Investing Activities (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Cash from Investing Activities data on file, last reported at $57.1 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 129.94% year-over-year to $57.1 million in Q1 2026; TTM through Mar 2026 was -$104.9 million, a 96.43% decrease from a year earlier, with the FY2025 full-year figure at -$137.2 million, down 184.71% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $57.1 million, up from $30.3 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for RYTM reached as high as $72.5 million in Q1 2022 and fell as low as -$246.3 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged -$6.2 million across 5 years, with a median of $22.6 million in 2023.
• Across the five-year window, Cash from Investing Activities slumped 662.57% in 2022 and jumped 731.1% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$40.8 million in 2022, then jumped by 155.52% to $22.6 million in 2023, then fell by 6.55% to $21.2 million in 2024, then surged by 43.44% to $30.3 million in 2025, then jumped by 88.0% to $57.1 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $57.1 million in Q1 2026, $30.3 million in Q4 2025, and -$246.3 million in Q3 2025.